Every material Form 8-K MIMEDX GROUP, INC. has filed with the SEC since July 29, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
MIMEDX reported third-quarter 2026 net sales of $62 million, down 45% from $114 million a year earlier, and a net loss of $9 million compared with net income of $17 million in the prior-year quarter. Wound sales fell 71% year over year, while Surgical sales rose 9%, and the company now expects 2026 net sales of $250 million to $260 million. The results and the pending Sanara MedTech acquisition, which still awaits FTC review, bear directly on shareholder value.
Q3 2026 net sales were $62 million versus $114 million a year earlier; diluted loss per share was $0.06 versus earnings of $0.11.
Adjusted EBITDA was $2 million in the quarter, compared with $35 million in the third quarter of 2025.
The company now expects 2026 net sales of $250 million to $260 million and fourth-quarter Adjusted EBITDA above the third quarter.
A patent license agreement with a wound care competitor provides $25 million payable in five $5 million installments, with the first already received.
MiMedx and Sanara MedTech each received a Second Request from the Federal Trade Commission on October 15, 2026, as part of the FTC's review of their proposed merger. The request extends the Hart-Scott-Rodino waiting period until 30 days after the parties substantially comply, which could delay closing; the filing gives no expected timing.
FTC issued Second Requests to MiMedx and Sanara on October 15, 2026.
Second Request extends the HSR Act waiting period until 30 days after substantial compliance, unless extended voluntarily or ended earlier by the FTC.
Completion still depends on HSR waiting period expiration and other closing conditions; MiMedx says it continues to work constructively with the FTC.
MiMedx reported second-quarter 2026 net sales of $64 million, down 35% from $99 million a year earlier, and a net loss of $15 million versus net income of $10 million. The company reiterated its full-year 2026 net sales outlook of $260 million to $290 million and announced a definitive agreement to acquire Sanara MedTech for a total enterprise value of about $350 million, which shareholders will weigh against the company's weaker results.
Q2 net sales were $64 million versus $99 million a year earlier; Wound sales fell 61% while Surgical sales rose 15%.
Q2 net loss was $15 million compared with net income of $10 million in the prior-year quarter; gross margin was 69% versus 81%.
Sanara shareholders would receive $33.00 in cash and 0.4735 MiMedx shares per share, valued at $35 per share; the deal is funded partly by a $300 million term loan from Hayfin Capital Management.
The deal is expected to close by the end of 2026, subject to Sanara shareholder approval and regulatory approvals; 2026 net sales guidance of $260 million to $290 million was reiterated.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every MIMEDX GROUP, INC. filing is on SEC EDGAR ↗. 8-K briefs of other companies →